Literature DB >> 34099486

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.

Oleg Melikhov1, Tatiana Kruglova2, Karine Lytkina3, Georgy Melkonyan3, Elena Prokhorovich4, Gleb Putsman5, Grigory Rodoman5, Arkady Vertkin4, Alena Zagrebneva2, Justin Stebbing6.   

Abstract

Entities:  

Keywords:  COVID-19; cytokines; therapeutics

Year:  2021        PMID： 34099486     DOI： 10.1136/annrheumdis-2021-220049

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  4 in total

Review 1.  Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review.

Authors:  Derma Dupuis; Kasinda Fritz; Emeka Ike; Oyinkansola Arogundade; Enoch O Adewara; Esther O Monday; Bolaji O Ayinde
Journal:  Cureus       Date:  2022-09-01

2.  Editorial: Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume I.

Authors:  Balakumar Chandrasekaran; Muthupandian Saravanan
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

3.  Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.

Authors:  Man Luo; Long Chen; Huan He; Fang He
Journal:  Eur J Med Res       Date:  2022-05-15       Impact factor: 4.981

4.  Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein.

Authors:  Jia Tong Loh; Joey Kay Hui Teo; Kong-Peng Lam
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.